Review summary
Teaching objective: Recognize new progressive neurologic symptoms (morning headache, word-finding pauses and a clumsy hand) as a reason for prompt contrast MRI of the brain in a 54-year-old Black woman who survived childhood polio, and then manage a newly diagnosed glioblastoma to current standards: dexamethasone only for symptomatic edema, at the lowest dose and tapered early, with glucose and stomach protection; no seizure prophylaxis when no seizure has occurred; CT to exclude another primary; awake craniotomy with language and motor mapping for maximal safe resection and an MRI within 48 hours; the WHO CNS5 1989 integrated diagnosis with IDH, TERT, EGFR, chromosome 7 and 10 and MGMT promoter methylation; radiotherapy 60 Gy in 30 fractions with daily temozolomide and Pneumocystis prophylaxis, then adjuvant temozolomide with tumor-treating fields; blood count and liver test monitoring; RANO 2.0 response assessment that allows for pseudoprogression; venous thromboembolism awareness; fall prevention for a woman whose new right-sided weakness meets a left leg weakened by polio in childhood; and early palliative care with advance care planning alongside treatment, on the NCCN CNS cancers guideline, the EANO 1989 diffuse glioma guideline and the ASCO-SNO glioma guideline. Her childhood care, given at a Black medical school because care nearer home was not offered to her, frames the commitment to equal access to a brain tumor center and clinical trials.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| June 23, 1940 | Born prematurely in Saint Bethlehem, near Clarksville, Tennessee, weighing about 4.5 pounds. | CLM-0001, CLM-0002 |
| about 1944 | Double pneumonia and scarlet fever at about four; polio in early childhood leaves the left leg partly paralyzed. | CLM-0003, CLM-0004 |
| about 1946 | Wears a metal leg brace and special shoe; weekly treatment at Meharry Medical College in Nashville, with massage at home. | CLM-0005 |
| about 1952 | Walks without the brace by about twelve, after taking it off in public at about nine and a half. | CLM-0006 |
| 1956 | Wins a bronze medal in the 4 x 100-meter relay at the Melbourne Olympics, at sixteen. | CLM-0007 |
| 1960 | Wins three gold medals at the Rome Olympics: 100 meters, 200 meters and the 4 x 100-meter relay. | CLM-0007 |
| 1992 | Returns to Tennessee as a vice president of a Nashville hospital. | CLM-0008 |
| November 12, 1994 | Dies of brain cancer at her home in Brentwood, Tennessee, at 54, after a diagnosis earlier that year, reported shortly after her mother's death. | CLM-0009, CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Wilma Glodean Rudolph was born on June 23, 1940, in Saint Bethlehem, Tennessee, near Clarksville, the twentieth of twenty-two children in her father's family. She grew up in a large, poor Black family in the segregated South. | confirmed | Wilma Rudolph (Olympedia athlete profile) supports Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports Norwood A. Wilma Rudolph supports Former Olympic sprinter Wilma Rudolph dies at 54 supports HISTMED Master Roster v3 context |
| D | She was born prematurely and weighed about 4.5 pounds at birth. Low birth weight is part of her early medical history; it carries no specific risk for the modern episode. |
confirmed | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports |
| D | She was often ill as a small child: at about age four she had double pneumonia followed by scarlet fever, and she had a number of other childhood illnesses before polio. | confirmed | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports Norwood A. Wilma Rudolph supports |
| D | In early childhood she had polio, which left her left leg paralyzed or partly paralyzed, with the foot turned inward. Sources give her age at the illness as an infant, about four, or about five. The documented polio is recorded as late effects of poliomyelitis in the past medical history and on the problem list, and the modern episode treats the once-weak left leg as a factor in mobility and falls. |
confirmed | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports Wilma Rudolph (Olympedia athlete profile) supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports |
| D | She wore a metal leg brace for several years (from about age six to ten in one account) and a specially made shoe. Once a week her mother took her by bus to Nashville, a 90-minute round trip, to the closest doctors who would treat her in the segregated South: physicians at Meharry Medical College, a historically Black medical school, fitted the brace and prescribed massage and heat. At home her family massaged the leg several times a day. Anchors the modern equity teaching: as a child she had to travel to a Black medical school for care that was not offered to her nearer home. |
confirmed | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports Norwood A. Wilma Rudolph supports |
| D | She later wrote that a doctor told her she would never walk again, and that her mother told her she would. Accounts of her recovery differ: she took the brace off in public at about nine and a half, could move about with the brace by eight, was running by eleven, and no longer needed the brace by about twelve. | confirmed | Norwood A. Wilma Rudolph supports Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports Former Olympic sprinter Wilma Rudolph dies at 54 supports |
| D | At sixteen she won a bronze medal in the 4 x 100-meter relay at the 1956 Olympic Games in Melbourne. At the 1960 Games in Rome she won gold in the 100 meters, the 200 meters and the 4 x 100-meter relay, the first American woman to win three gold medals in track and field at one Olympics. She ran for the Tennessee State University Tigerbelles. Her athletic career anchors the modern social history and the strength of the once-weak left leg. |
confirmed | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Wilma Rudolph (Olympedia athlete profile) supports Norwood A. Wilma Rudolph supports Former Olympic sprinter Wilma Rudolph dies at 54 supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports |
| D | After retiring from competition she worked in teaching, coaching and community work, founded an organization to help amateur track and field athletes, and in 1992 returned to Tennessee as a vice president of a Nashville hospital. Anchors the modern social history. |
confirmed | Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports Norwood A. Wilma Rudolph supports |
| D | In 1994, shortly after her mother's death, she was diagnosed with brain cancer; two accounts add throat cancer. Afterwards she seldom appeared in public, and she was in and out of hospitals for more than five months as the cancer spread. The anchor for the modern episode. The type, location and treatment of her brain cancer were not made public; the throat cancer is reported without detail and is not used. |
confirmed | Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports Former Olympic sprinter Wilma Rudolph dies at 54 supports |
| D | She died of brain cancer at her home in Brentwood, Tennessee, on November 12, 1994, at 54. The documented disease to which the synthetic diagnosis is linked. History only, stated without detail. |
confirmed | Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports Wilma Rudolph (Olympedia athlete profile) supports Former Olympic sprinter Wilma Rudolph dies at 54 supports Norwood A. Wilma Rudolph supports Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | active | |
| S | Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | active | CLM-0009 |
| S | Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | both_with_link | CLM-0009, CLM-0010 |
| S | Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | both_with_link | CLM-0003, CLM-0004, CLM-0005, CLM-0006 |
| S | Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | resolved | confirmed | active | |
| S | Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | resolved | confirmed | active | |
| S | Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1994-06-29 | Hemoglobin [Mass/volume] in Blood | 13.1 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-06-29 | Leukocytes [#/volume] in Blood by Automated count | 7.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-06-29 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-06-29 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1994-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1994-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1994-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 80 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1994-06-29 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1994-06-29 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6% Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes |
http://loinc.org · 4548-4 |
| S | 1994-06-29 | Karnofsky Performance Status score | 80 | http://loinc.org · 89243-0 |
| S | 1994-06-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1994-07-02 | Hemoglobin [Mass/volume] in Blood | 13 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-07-02 | Leukocytes [#/volume] in Blood by Automated count | 11.8 10*3/uL (high) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-07-02 | Platelets [#/volume] in Blood by Automated count | 270 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-07-02 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1994-07-02 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1994-07-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1994-07-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 83 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1994-07-02 | Glucose [Mass/volume] in Serum or Plasma | 138 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1994-07-02 | INR in Platelet poor plasma by Coagulation assay | 1 Reference 0.9-1.1 |
http://loinc.org · 6301-6 |
| S | 1994-07-02 | aPTT in Blood by Coagulation assay | 29 s Reference 25-37 s |
http://loinc.org · 3173-2 |
| S | 1994-07-02 | Karnofsky Performance Status score | 80 | http://loinc.org · 89243-0 |
| S | 1994-07-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 1994-07-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | http://loinc.org · 70274-6 |
| S | 1994-07-29 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-07-29 | Leukocytes [#/volume] in Blood by Automated count | 9.6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-07-29 | Neutrophils [#/volume] in Blood by Automated count | 7.2 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1994-07-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.1 10*3/uL Reference 1-4 10*3/uL |
http://loinc.org · 731-0 |
| S | 1994-07-29 | Platelets [#/volume] in Blood by Automated count | 248 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-07-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1994-07-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 85 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1994-07-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1994-07-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1994-07-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1994-07-29 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1994-07-29 | Glucose [Mass/volume] in Serum or Plasma | 168 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1994-07-29 | Karnofsky Performance Status score | 90 | http://loinc.org · 89243-0 |
| S | 1994-07-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 1994-09-14 | Hemoglobin [Mass/volume] in Blood | 11.9 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-09-14 | Leukocytes [#/volume] in Blood by Automated count | 3.6 10*3/uL (low) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-09-14 | Neutrophils [#/volume] in Blood by Automated count | 2.4 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1994-09-14 | Lymphocytes [#/volume] in Blood by Automated count | 0.5 10*3/uL (low) Reference 1-4 10*3/uL |
http://loinc.org · 731-0 |
| S | 1994-09-14 | Platelets [#/volume] in Blood by Automated count | 112 10*3/uL (low) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1994-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 88 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1994-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 U/L (high) Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1994-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 U/L (high) Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1994-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1994-09-14 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1994-09-14 | Karnofsky Performance Status score | 80 | http://loinc.org · 89243-0 |
| S | 1994-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | http://loinc.org · 44261-6 |
| S | 1994-10-09 | Hemoglobin [Mass/volume] in Blood | 12.2 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-10-09 | Leukocytes [#/volume] in Blood by Automated count | 4.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-10-09 | Neutrophils [#/volume] in Blood by Automated count | 2.9 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1994-10-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 10*3/uL (low) Reference 1-4 10*3/uL |
http://loinc.org · 731-0 |
| S | 1994-10-09 | Platelets [#/volume] in Blood by Automated count | 168 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-10-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1994-10-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 86 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1994-10-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1994-10-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1994-10-09 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1994-10-09 | Glucose [Mass/volume] in Serum or Plasma | 91 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1994-10-09 | Karnofsky Performance Status score | 80 | http://loinc.org · 89243-0 |
| S | 1994-10-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 1994-10-29 | Hemoglobin [Mass/volume] in Blood | 11.8 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1994-10-29 | Leukocytes [#/volume] in Blood by Automated count | 3.4 10*3/uL (low) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1994-10-29 | Neutrophils [#/volume] in Blood by Automated count | 1.9 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1994-10-29 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 10*3/uL (low) Reference 1-4 10*3/uL |
http://loinc.org · 731-0 |
| S | 1994-10-29 | Platelets [#/volume] in Blood by Automated count | 121 10*3/uL (low) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1994-10-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1994-10-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1994-10-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1994-06-29 | Body height | 180 cm | 8302-2 | S |
| 1994-06-29 | Body weight | 68 kg | 29463-7 | S |
| 1994-06-29 | Body mass index (BMI) [Ratio] | 21 kg/m2 | 39156-5 | S |
| 1994-06-29 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 1994-06-29 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 1994-06-29 | Heart rate | 72 /min | 8867-4 | S |
| 1994-06-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 1994-06-29 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1994-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1994-07-02 | Body height | 180 cm | 8302-2 | S |
| 1994-07-02 | Body weight | 67.8 kg | 29463-7 | S |
| 1994-07-02 | Body mass index (BMI) [Ratio] | 20.9 kg/m2 | 39156-5 | S |
| 1994-07-02 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 1994-07-02 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 1994-07-02 | Heart rate | 78 /min | 8867-4 | S |
| 1994-07-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 1994-07-02 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1994-07-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1994-07-29 | Body height | 180 cm | 8302-2 | S |
| 1994-07-29 | Body weight | 69.4 kg | 29463-7 | S |
| 1994-07-29 | Body mass index (BMI) [Ratio] | 21.4 kg/m2 | 39156-5 | S |
| 1994-07-29 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 1994-07-29 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 1994-07-29 | Heart rate | 76 /min | 8867-4 | S |
| 1994-07-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 1994-07-29 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1994-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1994-09-14 | Body height | 180 cm | 8302-2 | S |
| 1994-09-14 | Body weight | 67.2 kg | 29463-7 | S |
| 1994-09-14 | Body mass index (BMI) [Ratio] | 20.7 kg/m2 | 39156-5 | S |
| 1994-09-14 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 1994-09-14 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 1994-09-14 | Heart rate | 80 /min | 8867-4 | S |
| 1994-09-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 1994-09-14 | Body temperature | 36.8 Cel | 8310-5 | S |
| 1994-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1994-10-09 | Body height | 180 cm | 8302-2 | S |
| 1994-10-09 | Body weight | 66.6 kg | 29463-7 | S |
| 1994-10-09 | Body mass index (BMI) [Ratio] | 20.6 kg/m2 | 39156-5 | S |
| 1994-10-09 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 1994-10-09 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 1994-10-09 | Heart rate | 74 /min | 8867-4 | S |
| 1994-10-09 | Respiratory rate | 14 /min | 9279-1 | S |
| 1994-10-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1994-10-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1994-10-29 | Body height | 180 cm | 8302-2 | S |
| 1994-10-29 | Body weight | 66.9 kg | 29463-7 | S |
| 1994-10-29 | Body mass index (BMI) [Ratio] | 20.6 kg/m2 | 39156-5 | S |
| 1994-10-29 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 1994-10-29 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1994-10-29 | Heart rate | 76 /min | 8867-4 | S |
| 1994-10-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 1994-10-29 | Body temperature | 36.5 Cel | 8310-5 | S |
| 1994-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Vice president of a Nashville hospital; former Olympic champion sprinter, teacher and coach; runs a foundation that supports young track and field athletes
- S Lives in a suburb of Nashville; four grown children and a very large extended family nearby, and many friends from track and field
- S Remembers being told as a child that she would never walk again; wants to be told plainly what is happening and to stay as independent and active as she can
- S Never smoker; alcohol rarely; no drug use
- S Walks for exercise most days; drives herself to work
- S Menstrual history: periods stopped about two years ago; no hormone therapy
Functional status
- S Independent and working full time; walks without an aid; finds writing and buttons harder with the right hand for ten days. Examination: slight right pronator drift and right grip 4+/5, with full strength in both legs, a steady gait and no papilledema
Mental status
- S Alert and oriented; speech fluent with occasional pauses to find words and one or two substituted words; follows complex commands; repetition intact; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day
- S Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery
- S Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone
- S Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering
- S Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop
- S Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapy
- S Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia
- S Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea
- S Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6
Procedures and immunizations
Procedures
- S MRI of the brain with and without contrast, with diffusion and perfusion: a 3.8 x 3.2 cm ring-enhancing mass in the left posterior frontal lobe, involving the posterior inferior frontal gyrus and abutting the precentral gyrus, with central necrosis, raised relative cerebral blood volume in the enhancing rim, no restricted diffusion in the necrotic center, surrounding FLAIR signal from edema, and 5 mm rightward midline shift; no other lesion
- S CT of the chest, abdomen and pelvis with contrast to look for a primary cancer elsewhere: no mass, enlarged lymph node or other lesion
- S Functional MRI with diffusion tensor tractography for surgical planning: left-hemisphere language dominance; expressive language activation just in front of the mass; the corticospinal tract displaced but intact
- S Awake left frontal craniotomy with cortical and subcortical language and motor mapping and fluorescence-guided resection: gross total resection of the enhancing tumor, stopped at the mapped language sites. Pathology: glioblastoma, IDH-wildtype, CNS WHO grade 4 (necrosis and microvascular proliferation; IDH1 R132H immunostain negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; gain of chromosome 7 and loss of chromosome 10; CDKN2A homozygous deletion; histone H3 and BRAF wild-type). MGMT promoter methylated by pyrosequencing. Inpatient stay of three days, with mechanical and then low-molecular-weight heparin prophylaxis against venous thromboembolism from the day after surgery
- S MRI of the brain with and without contrast within 48 hours of surgery: no residual enhancing tumor; expected postoperative blood products; small area of restricted diffusion at the posterior margin from surgery; edema and midline shift less
- S Outpatient physical therapy assessment: mild weakness of the right hand and hip flexors after surgery; the left calf, weakened by polio in childhood, slightly smaller than the right with full strength; Timed Up and Go 9 seconds; home exercise program, home safety review and a fall plan
- S External beam radiotherapy to the resection cavity and margin, 60 Gy in 30 daily fractions over six weeks, with daily temozolomide; given in full on schedule
- S Outpatient palliative care consultation alongside cancer treatment: symptoms, coping, her understanding of the illness, goals and wishes, support for her family, and advance care planning; she named a health care agent (recorded in the confidential part of the chart) and completed an advance directive
- S MRI of the brain with and without contrast four weeks after chemoradiation: thin, smooth enhancement along the resection cavity with no nodular or new enhancement; FLAIR change around the cavity slightly less than after surgery; no new lesion. Treatment-related change; no progression (RANO 2.0); this scan is the new baseline
- S Advance care planning conversation, about 20 minutes, reviewing the advance directive completed with palliative care
Immunizations
- S 1994-10-29: Influenza vaccine, inactivated, trivalent, preservative free, this season
- S 1994-10-29: Pneumococcal conjugate vaccine PCV20
- S 1994-10-29: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D June 23, 1940: Born prematurely, weighing about 4.5 pounds (CLM-0002)
- D about 1944: Double pneumonia followed by scarlet fever at about age four, among other childhood illnesses (CLM-0003)
- D about 1945: Poliomyelitis in early childhood, leaving the left leg paralyzed or partly paralyzed, with the foot turned inward (CLM-0004)
- D about 1946: Metal leg brace and special shoe for several years; weekly treatment at Meharry Medical College in Nashville, with massage and heat, and massage at home several times a day (CLM-0005)
- D about 1952: Walking without the brace by about age 12; later an Olympic sprinter (CLM-0006, CLM-0007)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation | 1994-07-02 | completed | MRI the next morning; consultation three days after the first visit |
| Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength | 1994-07-29 | completed | Gross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal |
| Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule | 1994-09-14 | completed | Started 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a break |
| Dexamethasone tapered off within five weeks of surgery, with glucose back to normal | 1994-09-14 | completed | Off dexamethasone five weeks after surgery; glucose 96 mg/dL afterwards |
| No falls, and walking independently, through treatment | 1994-10-09 | completed | No falls; walks independently, with a cane only on uneven ground; home exercise program continued |
| Palliative care involved and her wishes recorded before adjuvant treatment begins | 1994-10-09 | completed | Palliative care consultation and advance directive completed eleven days before adjuvant cycle 1 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Urgent neuro-oncology consultation within one week, together with neurosurgery, to review the brain MRI with her and plan diagnosis and treatment if it shows a tumor | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 |
| New progressive focal neurologic symptoms are imaged promptly: MRI of the brain with and without contrast within 24 hours, with same-day emergency care if she worsens, has a seizure, vomits or becomes drowsy; blood count, chemistry and A1c; no driving until the cause is known | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 |
| Dexamethasone only for edema causing symptoms, at the lowest effective dose (4 mg twice a day), with famotidine and glucose checks, and tapered off as soon as possible after surgery | completed | GL-EANO-GLIOMA-2021, GL-NCCN-CNS-2026 |
| CT of the chest, abdomen and pelvis to exclude another primary; functional MRI with tractography; awake craniotomy with language and motor mapping for maximal safe resection; MRI within 48 hours; integrated WHO CNS5 diagnosis with IDH1 R132H immunostaining and IDH1 and IDH2 sequencing, ATRX, TERT promoter, EGFR, chromosome 7 and 10, CDKN2A, histone H3, BRAF and MGMT promoter methylation | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-WHO-CNS5-2021 |
| No antiseizure prophylaxis, because she has had no seizure; seizure first aid taught to her and her household; levetiracetam if a seizure occurs | completed | GL-SNO-EANO-AED-2021, GL-EANO-GLIOMA-2021 |
| Venous thromboembolism: mechanical and then low-molecular-weight heparin prophylaxis in hospital after surgery; no routine prophylaxis at home; she is taught the signs of leg clot and pulmonary embolism and to report them the same day | completed | GL-ASCO-VTE-2023, GL-NCCN-CNS-2026 |
| Radiotherapy 60 Gy in 30 fractions with temozolomide 75 mg/m2 daily, then six cycles of temozolomide 150 to 200 mg/m2 on days 1 to 5 of each 28-day cycle; Pneumocystis prophylaxis during concurrent treatment and while lymphopenia lasts; antiemetic before each dose; blood count weekly during chemoradiation and on day 22 of each adjuvant cycle; liver tests at baseline, mid-cycle 1 and before each cycle; MRI four weeks after radiotherapy and then every two to three months, read by RANO 2.0; clinical trial screening | completed | GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-STUPP-2005, GL-HEGI-2005, GL-TMZ-LABEL, GL-ASCO-SNO-2022, GL-RANO-2023 |
| Tumor-treating fields with adjuvant temozolomide, worn at least 18 hours a day, with scalp checks and skin care | completed | GL-EF14-2017, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 |
| Falls and mobility from the first visit: home safety review, fall plan, physical therapy assessment once the treatment plan is set, and a check at every visit of strength in both legs, since new right-sided weakness adds to a left leg weakened by polio in childhood; watch for new weakness, fatigue or pain that could signal post-polio syndrome | completed | GL-EFNS-PPS-2006, GL-EANO-GLIOMA-2021 |
| Early palliative care alongside cancer treatment: symptoms, coping, goals and advance care planning, and support for the people she chooses | completed | GL-ASCO-PALL-2024, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021 |
| Distress and depression screening at each visit, plain explanations with written information, and help to keep working as long as she wishes; she decides who receives information | completed | GL-USPSTF-DEP-2023, GL-CMID-2026, GL-NCCN-CNS-2026 |
Planned encounters
- 1994-06-29 — New headaches, word-finding pauses and right-hand clumsiness in a woman of 54: neurologic examination, MRI of the brain booked for the next morning, and neuro-oncology review booked (ENC-001)
- 1994-07-02 — MRI result: left frontal mass with edema; dexamethasone, CT staging, neuro-oncology consultation with neurosurgery, and preparation for awake craniotomy (ENC-002)
- 1994-07-29 — Review three weeks after awake craniotomy: pathology and molecular diagnosis, steroid taper, steroid-related hyperglycemia, falls, and the plan for radiotherapy with temozolomide (ENC-003)
- 1994-09-14 — End of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referral (ENC-004)
- 1994-10-09 — Post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care plan (ENC-005)
- 1994-10-29 — Periodic adult preventive visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Focused Visit (Care-plan review)
- Progress note 06 — Preventive Visit
- Neuro-Oncology referral
- Neuro-Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Progress note 06 — Preventive Visit (XML)
- Neuro-Oncology referral (XML)
- Neuro-Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Norwood A. Wilma Rudolph | National Women's History Museum | other |
| SRC-0002 | Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) | U.S. Olympic & Paralympic Museum | other |
| SRC-0003 | Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) | Tennessee Historical Society | other |
| SRC-0004 | Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia | Gale, via Encyclopedia.com | other |
| SRC-0005 | Wilma Rudolph (Olympedia athlete profile) | Olympedia (OlyMADMen) | other |
| SRC-0006 | Former Olympic sprinter Wilma Rudolph dies at 54 | Deseret News | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the urgency of imaging for new focal symptoms, the steroid dose and taper, the decision against seizure prophylaxis, the WHO CNS5 integrated diagnosis, the Stupp protocol doses and monitoring, the tumor-treating fields discussion, the RANO 2.0 reading of the first post-treatment MRI, and the fall plan for a polio survivor. |
| provenance review | not_started | Recent-death rule: only what she made public, what was reported during her life, and obituaries and reference accounts: the National Women's History Museum, the U.S. Olympic & Paralympic Museum, the Tennessee Encyclopedia, Women in World History, Olympedia and the Deseret News obituary. The type and treatment of her brain cancer were never made public; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named in the modern episode, and no health fact or decision is attributed to any real person. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.